937175-00-3

Upstream product

• 20781-20-8 2,4-Dimethoxybenzylamine 
• 937174-98-6 N-{[2,4-bis(methyloxy)phenyl]methyl}-2-bromo-N-{(2R)-2-hydroxy-3-[(phenylmethyl)oxy]propyl}propanamide 
• 937174-97-5 (S)-1-(benzyloxy)-3-((2,4-dimethoxybenzyl)amino)propan-2-ol 
• 937174-99-7 (6R)-4-{[2,4-bis(methyloxy)phenyl]methyl}-2-methyl-6-{[(phenylmethyl)oxy]methyl}-3-morpholinone 

Downstream Products

• 937175-01-4 (6R)-2-methyl-6-{[(phenylmethyl)oxy]methyl}morpholine 
• 937175-02-5 1,1-dimethylethyl (6R)-2-methyl-6-{[(phenylmethyl)oxy]methyl}-4-morpholinecarboxylate 
• 937175-04-7 1,1-dimethylethyl (6R)-2-methyl-6-({[(4-methylphenyl)sulfonyl]oxy}methyl)-4-morpholinecarboxylate 

Relevant academic research and scientific papers

METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY

Invented is the use of 1 H-imidazo[4,5-c]pyridin-2-yl compounds in the treatment of specified cancers.

INHIBITORS OF AKT ACTIVITY

Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.